CDR-Life Inc. has announced CDR-609 as its next clinical candidate. Built on the company’s proprietary M-gager platform, ...

Abion Inc. signed a potential $1.315 billion deal with an anonymous partner June 22, granting the counterparty exclusive ...

T-cell activity is often suppressed by the immunosuppressive nature of the tumor microenvironment, contributing to the ...

The U.K. National Health Service may or may not deploy transcatheter aortic valve replacement devices as widely as in the U.S., but the National Institute for Health and Care Excellence officially ...

Industry’s reaction to the U.S. FDA’s draft guidance for remote regulatory assessments included a request for more clarity on when the agency would issue a post-assessment report, but the final ...

Visceral leishmaniasis is a fatal disease caused by the Leishmania parasite, affecting organs such as the liver and spleen. Visceral leishmaniasis is considered a neglected tropical disease and is ...

Despite the approval of numerous antibody-drug conjugates (ADCs), their therapeutic index remains limited by off-target toxicity resulting from linker instability. To address this challenge, the ...

Hemab ApS recently presented preclinical data on its human monoclonal antibody against von Willebrand factor (vWF), HMB-002, for the treatment of von Willebrand disease.

Forsight Robotics Ltd. secured $125 million in series B financing for its Oryom platform, a robotic system for cataract surgery.

Muscarinic M4 receptor positive allosteric modulators are detailed in an Acadia Pharmaceuticals Inc. patent. They are reported to be useful for the treatment of Alzheimer’s disease, pain, ...

BioWorld tracked 223 clinical trial updates across phases I to III in May 2025, marking an increase from 197 in March and 151 in April. Among these, 17 trials reported positive phase III results, ...

Bristol Myers Squibb Co. has identified new GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.